About Us
23andMe Therapeutics is powered in part by genetic and phenotypic information from research-consented members of the 23andMe community, who we consider to be part of our team in our discovery and development efforts. With their participation, our researchers are able to identify and pursue novel targets that are central mediators of biological processes relevant to the immune system.
CEO, Co-Founder
Anne is CEO and Co-Founder of 23andMe. Since co-founding 23andMe in 2006, Anne has pioneered the direct-to-consumer DNA testing space and the large-scale application of human genetic data to therapeutic development. As CEO, she has led the development of the only personal genetic test with FDA authorization to deliver health information directly to consumers, and the development of therapeutic programs and capabilities to address serious unmet medical needs.
Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare before pivoting to building a business that helps people prevent illness rather than profit from it. She received a B.S. in Biology from Yale University.
Head of Therapeutics Development
Jennifer is the Head of Therapeutics Development at 23andMe. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies, and leads a group that includes preclinical and clinical development and drug manufacturing.
Jennifer has thirty years of drug development experience spanning academia, government, large pharma and small biotech. She has been the Chief Medical Officer at Loxo Oncology and has led early- and late-stage clinical development at Genentech/Roche that led to multiple drug approvals worldwide. She has degrees from Caltech, Georgetown, and Duke and has held academic positions at the National Cancer Institute and the National Naval Medical Center, where she was an attending physician for breast cancer patients. She has co-authored papers appearing in the New England Journal of Medicine, Science, Cancer Discovery, Journal of Clinical Oncology, and Nature Reviews Cancer.
Vice President, Human Genetics
Adam joined 23andMe in 2015 and is the Vice President of Human Genetics. Adam is responsible for computational approaches to target discovery via statistical genetics and machine learning approaches.
Prior to joining 23andMe, Adam pursued an academic career at Albert Einstein College of Medicine, with a focus on large-scale genomic analyses and statistical algorithm development. He received a MSci in Physics from the University of Bristol (UK), and a DPhil in Statistical and Population Genetics from the University of Oxford.
